Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

Journal of Viral Hepatitis

Volumn 14, Issue 2, 2007, Pages 107-115

  Deuffic Burban, S ^a   Poynard, T ^b   Sulkowski, M S ^c   Wong, J B ^d  

^a IESEG School of Management   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Back calculation; Chronic hepatitis C; Human immunodeficiency virus; Markov model; Mortality predictions

Indexed keywords

AGE; ANTIVIRAL THERAPY; ARTICLE; EPIDEMIC; GENDER; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MATHEMATICAL MODEL; MORTALITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; UNITED STATES;

FORECASTING; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; MODELS, STATISTICAL; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 33846403737     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00785.x     Document Type: Article

References (42)

1. World Health Organization. Hepatitis C. Wkly Epidemiol Rec 1997; 72: 65-72.
2. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-344.
3. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
4. Palella Jr FJ., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
5. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-782.
6. Wong J, McQuillan GM, McHutchinson JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
7. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-S34.
8. Salomon JA, Weinstein JS, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156: 761-773.
9. Law MG. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol 1999; 14: 1100-1107.
10. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000; 14: 575-580.
11. Deuffic S, Buffat L, Poynard T, Valleron A-J. Modeling the HCV epidemic in France. Hepatology 1999; 29: 1596-1601.
12. Deuffic-Burban S, Wong JB, Valleron A-J, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-326.
13. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron A-J. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006; 44: 455-461.
14. Rosenberg PS, Biggar RJ, Goedert JJ, Gail MH. Backcalculation of the number with human immunodeficiency virus infection in the United States. Am J Epidemiol 1991; 133: 276-285.
15. Rosenberg PS, Gail MH, Carroll RJ. Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. Stat Med 1992; 11: 1633-1655.
16. Pagliaro L, Peri V, Linea C, Camma C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Italian J Gastroenterol Hepatol 1999; 31: 28-44.
17. Degos F, Christidis C, Ganne-Carrié N et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136.
18. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-65.
19. Manns M, McHutchinson JG, Gordon S et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
20. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35: 266-269.
21. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380.
22. Fong KW, Jefferson TH, Suyehiro T, Walton L. Guide to SLA-TEC Common Mathematical Library. In: Version 4.1 ed. United States Department of Energy National Laboratories, 1993.
23. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963; 11: 431-441.
24. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Statist 1983; 37: 36-48.
25. Brookmeyer R, Gail M. The minimum size of the AIDS epidemic in the United States. Lancet 1986; ii: 1320-1322.
26. Rosenberg PS, Biggar RJ. Trends in HIV incidence among young adults in the United States. JAMA 1998; 279: 1894-1899.
27. Rosenblum L, Buehler JW, Morgan MW et al. The completeness of AIDS case reporting, 1988: a multisite collaborative surveillance project. Am J Public Health 1992; 82: 1495-1499.
28. Klevens RM, Fleming PL, Li J et al. The completeness, validity, and timeliness of AIDS surveillance data. Ann Epidemiol 2001; 11: 443-449.
29. Buehler JW, Berkelman RL, Stehr-Green JK. The completeness of AIDS surveillance. J Acquir Immune Defic Syndr 1992; 5: 257-264.
30. Karon JM, Rosenberg PS, McQuillan G et al. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996; 276: 126-131.
31. Tassie JM, Grabar S, Lancar R et al. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. J Acquir Immune Defic Syndr 2002; 30: 81-87.
32. Fleming PL, Byers RH, Sweeney PA et al. HIV prevalence in the United States, 2000. In: 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, in Seattle, WA, USA.
33. Becker NG, Marschner IC. A method for estimating the age-specific relative risk on HIV infection from AIDS incidence data. Biometrika 1993; 80: 165-178.
34. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
35. Alter MJ, Hadler SC, Judson FN et al. Risk factors for acute non-A, non-B hepatitis in United States and association with hepatitis C virus infection. JAMA 1990; 264: 2231-2235.
36. Alter HJ, ConryCantilena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26: S29-S33.
37. Tanaka Y, Hanada K, Mizokami M et al. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584-15589.
38. Mizokami M, Tanaka Y. Molecular evolutionary analysis predicts the incidence of hepatocellular carcinoma in the United States and Japan. Cancer Chemother Pharmacol 2004; 54(Suppl. 1): S83-S86.
39. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991; 253: 37-42.
40. Bacchetti P, Segal MR, Hessol NA, Jewell NP. Different AIDS incubation periods and their impacts on reconstructing human immunodeficiency virus epidemics and projecting AIDS incidence. Proc Natl Acad Sci USA 1993; 90: 2194-2196.
41. Detels R, Muñoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280: 1497-1503.
42. Tarwater PM, Mellors J, Gore ME et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001; 154: 675-681.